Kieseier BC - Search Results

1

CD19 as a molecular target in CNS autoimmunity.

Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V. Stüve O, et al. Among authors: kieseier bc. Acta Neuropathol. 2014 Aug;128(2):177-90. doi: 10.1007/s00401-014-1313-z. Epub 2014 Jul 4. Acta Neuropathol. 2014. PMID: 24993505 Free PMC article. Review.

2

Alemtuzumab: the advantages and challenges of a novel therapy in MS.

Menge T, Stüve O, Kieseier BC, Hartung HP. Menge T, et al. Among authors: kieseier bc. Neurology. 2014 Jul 1;83(1):87-97. doi: 10.1212/WNL.0000000000000540. Epub 2014 Jun 11. Neurology. 2014. PMID: 24920854 Review.

3

Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.

Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Awad A, et al. J Neuroimmunol. 2010 Feb 26;219(1-2):1-7. doi: 10.1016/j.jneuroim.2009.09.002. Epub 2009 Sep 25. J Neuroimmunol. 2010. PMID: 19782408 Review.

4

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Aktas O, Kieseier B, Hartung HP. Aktas O, et al. Trends Neurosci. 2010 Mar;33(3):140-52. doi: 10.1016/j.tins.2009.12.002. Epub 2010 Jan 4. Trends Neurosci. 2010. PMID: 20045200 Review.

5

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Menge T, et al. Among authors: kieseier bc. Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. Drugs. 2008. PMID: 19016573 Review.

6

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Stüve O, et al. Among authors: kieseier bc. Arch Neurol. 2009 Feb;66(2):259-61. doi: 10.1001/archneurol.2008.551. Arch Neurol. 2009. PMID: 19204165

7

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC. Warnke C, et al. Among authors: kieseier bc. Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627. Drug Des Devel Ther. 2010. PMID: 20689698 Free PMC article. Review.

8

A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

Kieseier BC, Stüve O. Kieseier BC, et al. Nat Rev Neurol. 2011 May;7(5):255-62. doi: 10.1038/nrneurol.2011.41. Epub 2011 Apr 5. Nat Rev Neurol. 2011. PMID: 21467994 Review.

9

Cladribine as a therapeutic option in multiple sclerosis.

Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Warnke C, et al. Among authors: kieseier bc. Clin Immunol. 2012 Jan;142(1):68-75. doi: 10.1016/j.clim.2011.05.009. Epub 2011 Jun 1. Clin Immunol. 2012. PMID: 21733757 Review.

10

Targeting two-pore domain potassium channels - a promising strategy for treating T cell mediated autoimmunity.

Kieseier BC, Hartung HP. Kieseier BC, et al. Exp Neurol. 2013 Sep;247:286-8. doi: 10.1016/j.expneurol.2013.01.016. Epub 2013 Jan 23. Exp Neurol. 2013. PMID: 23353639

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

384 results

Search Page